Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sandoz outlines growth and efficiency strategy

Sandoz outlines growth and efficiency strategy

19th June 2014

Sandoz has discussed the steps it is taking to ensure a continuation of its recent growth during an investor meeting held by parent company Novartis.

During the Meet Novartis Management investor day, more than 20 top Novartis bosses met with around 100 investors and analysts in Basel to discuss the future direction of its various divisions, including Sandoz.

Currently the the second-largest generics player in the world, Sandoz outperformed the market in all regions in 2013,a trend that is expected to continue as it develops more complex, differentiated generics and biosimilars.

From 2007 to 2012, global sales of products set to lose patent protection in the following year came to $198 billion (116.17 billion pounds), and this is expected to rise to $215 billion from 2013 to 2018.

Efforts will also be made to enhance productivity and efficiency, maintaining the progress seen in the last five years.

Richard Francis, Sandoz division head, said: "Future patent expiries remain strong, but there is a shift to complex products, validating the Sandoz strategy, which is deeply rooted in innovation. We're continuing to find ways to become more efficient and improve our margins."

Mr Francis was placed in charge of Sandoz in April 2014, succeeding Jeff George, who took over leadership of fellow Novartis subsidiary Alcon.ADNFCR-8000103-ID-801729543-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.